請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/26859
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 鄭景暉 | |
dc.contributor.author | Ting-Ting Yang | en |
dc.contributor.author | 楊婷婷 | zh_TW |
dc.date.accessioned | 2021-06-08T07:29:17Z | - |
dc.date.copyright | 2008-08-13 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-07-03 | |
dc.identifier.citation | 1. Akiba J, Yano H, Ogasawara S, Higaki K, Kojiro M. Expression and function of interleukin-8 in human hepatocellular carcinoma. Int J Oncol 2001; 18: 257-264
2. Arsura M, Cavin LG. Nuclear factor-κB and liver carcinogenesis. Cancer Lett. 2005;229:157-169 3. Benn J, Su F, Doria M, Schneider RJ. Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases. J Virol. 1996;70:4978-4985 4. Bhide SV, Shivapurkar NM, Gothoskar SV and Ranadive KJ. Carcinogenicity of betel nut ingredients: feeding mice with aqueous extract and the polyphenol fraction of betel nut. Br J Cancer 1979;40:922-926 5. Bhide SV, Shivapurkar NM, Gothoskar SV, Ranadive KJ: Carcinogenicity of betel quid ingredients: feeding mice with aqueous extract and the polyphenol fraction of betel nut. Br J Cancer 1979;40:922-6. 6. Boldt S,Weidle UH, Kolch W. The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis 2002;23:1831-8. 7. Boyland E, Nery R. Mercapturic acid formation during the metabolism of arecoline and arecaidine in the Rat. Biochem. J. 1969; 113:123-130 8. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, Masferrer JL, Dannenberg AJ. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 1999 Mar 1;59(5):991-4. 9. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, et al. Cyclooxygenase-2 expression is upregulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59:991-4. 10. Chatterjee A, Deb S. Genotoxic effect of arecoline given either by the peritoneal or oral route in murine bone marrow cells and the influence of N-acetylcysteine. Cancer Lett. 1999 May 3;139(1):23-31. 11. Chirillo P, Falco M, Puri PL, Artini M, Balsano C, Levrero M, Natoli G. Hepatitis B virus pX activates NF-kappa B-dependent transcription through a Raf-independent pathway. J.Virol.1996;70:641-646 12. Chou WW, Guh JY, Tsai JF, Hwang CC, Chen HC, Huang JS, Yang YL, Hung WC, Chuang LY. Arecoline-induced growth arrest and p21WAF1 expression are dependent on p53 in rat hepatocytes. Toxicology 2008; 243(1-2):1-10 13. Colgrove R, Simon G, GanemD. Transcriptional activation of homologous and heterologous genes by the hepatitis B virus X gene product in cells permissive for viral replication. J Virol 1989;63:4019-4026 14. Dave BJ, Trivedi AH, Adhvaryu SG. In vitro genotoxic effects of areca nut extract and arecoline. J Cancer Res Clin Oncol. 1992;118(4):283-8. 15. DiBisceglie AM (1999). Malignant neoplasms of the liver. In: Schiff’s disease of the liver 8 th edn. Schiff ER, Sorrell MF, Maddrey WC, (eds) pp.1281-1304 Lippincott-Raven Publishers: Philidelphia 16. Dusgupta R, Saha I, Pal S, Bhattacharyya A, Sa G, Nag TC, Das T, Maiti BR. Immunosuppression, hepatotoxicity and depression of antioxidant status by arecoline in albino mice. Toxicology 2006;227:94-104 17. Eferl R, Wagner EF. AP-1: A double-edged sword in tumorigenesis. Nature Rev. Cancer. 2003,3:859-868 18. El-Deiry WS, Tokino T, Velculesu VE, Levy DB, Parsons R, Trent J, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumour suppression. Cell 1993;75:817–825 19. Guan YS, La Z, Yang L, He Q, Li P. p53 gene in treatment of hepatic carcinoma : Status quo. World J Gastroenterol 2007;Feb 21;13(7):985-992 20. Gupta PC, Ray CS. Epidemiology of betel quid usage. Ann Acad Med Singapore. 2004 Jul;33(4 Suppl):31-6. 21. Gunter S, Li BC, Miska S, Kruger DH, Meisel H, Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 1995;69:5437-5444 22. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting Cip1 is a potent inhibitor of G1 cyclin dependent kinase. Cell 1993;75:805–816 23. Hazeki K, Nigorikawa K, and Hazeki O. Role of Phosphoinositide 3-Kinase in innate immunity. Biol. Pharm. Bull. 2007; 30(9):1617-1623 24. Ho JW, Poon RT, Tong CS, Fan ST. Clinical significance of serum vascular cell adhesion molecule-1 levels in patients with hepatocellular carcinoma. World J Gastroenterol 2004;10(14):2014-2018 25. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253:49–53 26. Hsiang CY, Wu SL, Chen JC, Lo HY, Li CC, Chiang SY, Wu HC, Ho TY. Acetaldehyde induces matrix metalloproteinase-9 gene expression via nuclear factor-κB and activator protein 1 signaling pathways in human hepatocellular carcinoma cells: Association with the invasive potential. Toxicology Lett 2007;171:78-86. 27. IARC. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans 37, IARC, Lyon, 1985 28. Indilman R, De Maria N, Colantoni A and Van Thiel DH. Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma. J Viral Hepatitis 1998;5:285-299 29. Jeng JH, Chang MC, Hahn LJ. Role of areca nut in betel quid-associated chemical carcinogenesis: current awareness and future perspectives. Oral Oncol. 2001 Sep;37(6):477-92. 30. Jeng JH, Hahn LJ, Lin BR, Hsieh CC, Chan CP, Chang MC. Effects of areca nut, inflorescence piper betel extracts and arecoline on cytotoxicity, total and unscheduled DNA synthesis in cultured gingival keratinocytes. J Oral Pathol Med 1999;28:64-71 31. Jeng JH, Ho YS, Chan CP, Wang YJ, Hahn LJ, Lei D, Hsu CC, Chang MC. Areca nut extract up-regulates prostaglandin production, cyclooxygenase-2 mRNA and protein expression of human oral keratinocytes. Carcinogenesis 2000;21:1365-1370 32. Jeng JH, Kuo ML, Hahn LJ, Kuo MYP. Genotoxic and nongenotoxic effects of betel quid ingredients on oral mucosal fibroblasts in vitro. J Dent Res 1994;73:1043-9 33. Jeng JH, Wang YJ, Chiang BL, Lee PH, Chan CP, Ho YS, Wang TM, Lee JJ, Hahn LJ, Chang MC. Roles of keratinocyte inflammation in oral cancer: regulating the prostaglandin E2, interleukin-6 and TNF-α production of oralepithelial cells by areca nut extract and arecoline. Carcinogenesis 2003;24(8):1301-1315 34. Jeng JH, Wang YJ, Chiang BL,Lee PH, Chan CP, Ho YS, Wang TM, Lee JJ, Hahn LJ, Chang MC. Roles of keratinocyte inflammation in oral cancer: regulating the prostaglandin E2, interleukin-6 and TNF-a production of oral epithelial cells by areca nut extract and arecoline. Carcinogenesis 2003;24:1301-1315. 35. Johnson GL, Lapadat R. Mitogen activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-2. 36. Kao JH. Hepatitis B Virus Genotypes and Hepatocellular Carcinoma in Taiwan. Intervirology 2003;46:400-407 37. Kennedy NJ, Davis RJ. Role of JNK in tumor development. Cell cycle 2003;2:199-201. 38. Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991;351:317-320 39. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J. 2000;351:289-305 40. Lai BS, Chi TY, Chen G. Different levels of p53 induced either apoptosis or cell cycle arrest in a doxycycline-regulated hepatocellular carcinoma cell line in vitro. Apoptosis 2007;12:387–393 41. Lee Y, Park US, Choi I, Yoon SK, Park YM, Lee YL. Human interleukin 6 gene is activated by hepatitis B virus-X protein in human hepatoma cells. Clin Cancer Res. 1998;4:1711-1717. 42. Lin SC, Lu SY, Lee SY, Lin CY, Chen CH, Chang KW. Areca (betel) nut extract activates mitogen-activated protein kinases and NF-kappaB in oral keratinocytes. Int J Cancer. 2005 Sep 10;116(4):526-35. 43. Liu CJ, Kao JH, Chen DS. Therapeutic implications of hepatitis B virus genotypes. Liver Int. 2005; 25: 1097-1107 44. Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, Hasnian SS, Leung N, Lesmana L, Phiet PH, Sjalfoellah Noer HM, Sollano J, Sun HS, Xu DZ. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000;15:1356-1361 45. Müller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M, Krammer PH. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp. Med. 1998; 188:2033-2045 46. Nair J, Ohshima H, Friesen M, Croisy A, Bhide SV, Bartsch H. Tobacco-specific and betel nut-specific N-nitroso compounds: occurrence in saliva and urine of betel quid chewers and formation in vitro by nitrosation of betel quid. Carcinogenesis.1985 Feb;6(2):295-303 47. Nair UJ, Floyd RA, Nair J, Bussachini V, Friesen M, Bartsch H. Formation of reactive oxygen species and of 8-OH-dG in DNA in vitro with betel quid ingredients. Chem-Biol Interact 1987;63:157-69 48. Nair UJ, Friesen M, Richard I, MacLennan R, Thomas S, Bartsch H. Effect of lime composition on the formation of reactive oxygen species from areca nut extract in vitro. Carcinogenesis 1990;11:2145-8 49. Nair UJ, Obe G, Friesen M, Goldberg MT, Bartsch H. Role of lime in the generation of reactive oxygen species from betel-quid ingredients. Environmental Health Perspectives 1992;98:203-205 50. Nishikawa A, Prokopczyk B, Rivenson A, Zang E and Hoffmann D. A study of betel quid carcinogenesis-VIII. Carcinogenicity of 3 (methylnitrosamino) propionaldehyde in F344 rats. Carcinogenesis 1992;13:369-372 51. Okabe K, Kato I, Sato S, Kashiwabara T, Furuta S, Sato H, Tanikawa K, Kumashiro R, Kanayama M. Clinical evaluation of tissue plasminogen activator (t-PA) levels in patients with liver diseases. Gastroenterol Jpn. 1992; 27(1):61-8 52. Palanki MSS. Inhibitors of AP-1 and NF-κB mediated transcriptional activation: therapeutic potential in autoimmune diseases and structural diversity. Curr Med Chem. 2002;9:219-227 53. Philips DH. 1994 ;DNA adducts derived from safrole, estragole and related compounds, and from benzene and its metabolites. In: DNA adducts: identification and biological significance. Hemminki K, Dipple A, Shuker DEG, Kadlubar FF, Segerback D, Bartsch H, (eds) pp.131-140. International Agency for Research on Cnacer Research: Lyon, France 54. Phukan RK, Ali MS, Chetia CK, Mahanta J. Betel nut and tobacco chewing; potential risk factors of cancer of oesophagus in Assam, India. Br J Cancer. 2001 Sep 1;85(5):661-7.; 55. Prokopczyk B, Rivenson A, Bettinato P, Bertinato P, Brunnemann D and Hoffmann D. 3-(Methylnitorsamino)propionitrile: Occurrence in saliva of betel quid chewers, carcinogenicity, and DNA methylation in F344 rats. Cancer Res 1987;47:467-471 56. Qin LX, Tang ZY. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol. 2002;8(3):385-392. 57. Saikia JR, Schneeweiss FHA, Sharan RN. Arecoline-induced changes of poly-ADP-ribosylation of cellular proteins and its influence on chromatin organization. Cancer Lett 1999;138:59-65. 58. Seo DD, Lee HC, Kim HJ, Min HJ, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ, Yu E, Chun SY. Neural cadherin overexpression is a predictive marker for early postoperative recurrence in hepatocellular carcinoma patients. J Gastroenterol Hepatol. 2007 Oct 17. [Epub ahead of print] 59. Sharan RN. Association of betel nut with carcinogenesis. Cancer J 1996;9:13-9.60. Stadheim TA, Xiao H, Eastman A. Inhibition of extracellular signal regulated kinase (ERK) mediates cell cycle phase independent apoptosis in vinblastine-treated ML-1 cells. Cancer Res 2001;61;1533-40. 61. Su F, Schneider J. Hepatitis B virus HBx protein activates transcription factor NF-kappa B by acting on multiple cytoplasmic inhibitors of rel-related proteins. J.Virol.1996;70:4558-4566 62. Sundqvist K, Liu Y, Nair J, Bartsch H, Arvidson K, Grafstrom RC. Cytotoxic and genotoxic effects of areca nut related compounds in cultured human buccal epithelial cells. Cancer Res 1989;49:5294-8 63. Surh YJ, Kundu JK, Na HK, Lee JS. Redox-sensitive transcription factors as prime targets for chemoprevention with anti-inflammatory and antioxidative phytochemicals. J. Nutr. 2005;135: 2993S–3001S 64. Szabo-Fresnais N, Blondeau JP, Pom´erance M. Activation of the cAMP pathway synergistically increases IL-1-induced IL-6 gene expression in FRTL-5 thyroid cells: Involvement of AP-1 transcription factors. Mol Cell Endocrinol. 2008; 284: 28–37. 65. Tang H, Delgermaa L, Huang F, Oishi N, Liu L, He F, Zhao L, Murakami S. The transcriptional transactivation function of HBx protein is important for its augmentation role in hepatitis B virus replication. J Virol 2005;79:5548-5556 66. Tsai JF, Chuang LY, Jeng JE, Ho MS, Hsieh MY, Lin ZY and Wang LY. Betel quid chewing as a risk factor for hepatocellular carcinoma: a case control study. Br J Cancer 2001;84(5):709-713. 67. Tsai JF, Jeng JE, Chuang LY, Ho MS, Ko YC, Lin ZY, Hsieh MY, Chen SC, Chuang WL, Wang LY, Yu ML, Dai CY, Ho C. Habitual betel quid chewing as a risk factor for cirrhosis. A case study. Medicine 2003;82(5)365-372 68. Tsai JF, Jeng JE, Chuang LY, Ho MS, Ko YC, Lin ZY, Hsieh MY, Chen SC, Chaung WL, Wang LY, Yu ML, Dai CY. Habitual betel quid chewing and risk for hepatocellular carcinoma complicating cirrhosis. Medicine 2004;83:176-187. 69. Valko M, Rhodes CJ, Monco J, Izakovic M, Mazura M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem-Bio Interact. 2006;160:1-40 70. Wang LY, You SL, Lu SN, Ho HC, Wu MH, Sun CA, Yang Hi, Chen JC. Risk of hepatocellular carcinoma and habits of alcohol drinking, betel quid chewing and cigarette smoking: a cohort of 2416 HBsAg-seropositive and 9421 HBsAg-seronegative male residents in Taiwan. Cancer Causes Control 2003;14:241-250. 71. Wu HL, Cheng PJ, Lin MH, Chen DS. Temporal aspects of major viral transcript expression in HepG2 cells transfected with cloned Hepatitis B Virus DNA: with emphasis on the X transcript. Virology 1991;185:644-651 72. Wu HL, Chen PJ, Tu SJ, Lin MH, Lai MY, Chen DS. Characterization and genetic analysis of alternatively spliced transcripts of hepatitis B virus in infected human liver tissues and transfected HepG2 cells. J Virol. 1991;65:1680-1686 73. Wu HL, Huang LR, Huang CC, Lai HL, Liu CJ, Huang YT, Hsu YW, Lu CY, Chen DS, ChenPJ. RNA interference-mediated control of Hepatitis B Virus and emergence of resistant mutant. Gastroenterology 2005;128:708-716 74. Wu HM, Boucher JB, Chiu YH, Liao CS, Chen HH. Impact of chewing betel-nut (Areca catechu) on liver cirrhosis and hepatocellular carcinoma: a population-based study from an area with a high prevalence of hepatitis B and C infections. Public Health Nutr. 2008; 15:1-7 75. Wu MT, Lee YC, Chen CJ, Yang PW, Lee CJ, Wu DC, Hsu HK, Ho CK, Kao EL, Lee JM. Risk of betel chewing for oesophageal cancer in Taiwan. Br J Cancer. 2001 Sep 1;85(5):658-60. 76. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. P21 is a universal inhibitor of cyclin kinase. Nature 1993;366:701–704 77. Yun C, Um HR, Jin YH, Wang JH, Lee MO, Park S, Lee JH, Cho H. NF-κB activation by hepatitis B virus X (HBx) protein shifts the cellular fate toward survival. Cancer Lett. 2002; 184:97-104 78. Zheng Y, Chen WL, Ma WL. Chang C, Ou JH. Enhancement of gene transactivation activity of androgen receptor by hepatitis B virus X protein. Virology 2007;363:454-461. 79. Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006; 12(8):1175-1181 80. Zhou XD. Recurrence and metastasis of hepatocellular carcinoma: progress and prospects. HBPD Int. 2002;1:35-41 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/26859 | - |
dc.description.abstract | 嚼食檳榔在東南亞國家是一非常普遍之口腔嗜好,目前在全世界有六億之嚼食人口。嚼食檳榔已知為造成口腔白斑、口腔黏膜下纖維化、口腔癌及食道癌之主要危險因子之一。嚼食檳榔者由於可能會將唾液完全吞入上消化道,因此檳榔塊所產生的嚴重毒性作用也會在口腔以外的部位發生。許多的研究在動物實驗中發現檳榔子萃取物會對肝細胞造成基因毒性及細胞毒性。此外,轉錄因子AP-1及NF-κB與肝癌有很強烈的相關性,並在許多報告中皆指出肝炎病毒X 蛋白可活化AP-1 及NF-κB。近幾年來持續有針對於嚼食檳榔與肝癌相關性之流病報告,結果指出嚼食檳榔為一造成肝癌之獨立危險因子,並也對於慢性B 型肝炎病毒感染相關的肝癌有加成效果。由於台灣為B 肝病毒高帶原率的國家,因此本實驗欲針對檳榔成份合併B 型肝炎病毒兩大因素對於AP-1、NF-κB 轉錄因子分子調控機制與肝癌形成的關係進行探討。藉由報導基因分析我們發現檳榔子萃取物與檳榔素分別在800 μg/ml 及0.8 mM 的濃度下對於AP-1 及NF-κB 轉錄因子有活化之作用。在檳榔成份活化AP-1 的部分主要是經由Ras/Raf/ERK/MEK路徑,而在相同濃度的檳榔子萃取物作用之下,NF-κB 的部份則主要是經由PKC及MEK/ERK 但不經由Ras 路徑來達到活化。在B 肝病毒X 蛋白的存在下,對於檳榔子萃取物活化AP-1 及NF-κB 有協同活化效益,但對檳榔素則只有加成作用。我們利用RT-PCR 或西方墨點法研究檳榔子萃取物及檳榔素是否會誘導一些具有肝癌侵略性代表意義之相關指標分子的表現,結果發現檳榔子萃取物會增加tPA, PAI-1, IL-6 及IL-8 的基因表現,在HBx 存在下,IL-8 表現增加較為明顯; 檳榔素則會增加N-Cadherin, VCAM-1。總結來說,檳榔成份會對於轉錄因子AP-1及NF-κB 有活化作用,並在HBx 的存在下結果更加顯著,此外還會造成一些具有肝腫瘤侵略性之指標性分子之表現。因此我們提供了一個合併檳榔成份與肝炎病毒對於肝癌形成影響之可能分子機制,而對於臨床上之蘊含意義為在B 型肝炎病毒的帶原下,若加上嚼食檳榔之習慣可能會提高肝癌形成之危險性。 | zh_TW |
dc.description.abstract | Betel quid (BQ) chewing is a common oral habit in Southeast Asian contries. There are about six hundred million BQ chewers in the world. The evidence of BQ chewing as one of the major risk factors leading to leukoplakia, oral submucous fibrosis, oral cancer and esophagus cancers have been well published. The BQ chewers may swallow saliva completely and therefore the severe toxic effects of BQ may occurs at sites other than the oral cavity. The animal studies have demonstrated that the betel quid components causes hepatotoxicity and the genotoxic effects of hepatocytes. In addition, transcriptional factors AP-1 and NF-κB has strong correlation with liver carcinogenesis and can be activated by X protein of the HBV. Recently, the epidemiology reports have shown that the habitual BQ chewing is an independent risk factors of hepatocellular carcinoma (HCC) and may have an addiditve effect with HBV infection. The HBsAg carrier rate in general population of Taiwan is one of the highest in the world. In our study, we like to investigate the AP-1 and NF-κB molecular mechanisms combine with HBV factors for the association of BQ components with the development of HCC. By using the luciferase assay, we found that the AN extract (ANE) 800 μg/ml and Arecoline (ACO) 0.8 mM induced AP-1 binding site activation mainly through Ras/Raf/MEK/ERK pathways. At the same ANE concentrations, NF-κB binding sites were activated mainly through PKC and MEK/ ERK pathways, but not the Ras pathways. In the presence of HBx protein, ANE-induced AP-1 and NF-κB is synergistically activated and with MEK/ERK pathways involvement. Compare with ANE, ACO-induced AP-1 and NF-κB activation in the presence of HBx protein only reach to the additive effects. At the mRNA level, some HCC invasiveness markers were induced by ANE (tPA, PAI-1 and IL-6 ) or ACO (N-Cadherin, VCAM-1). At the protein level, ANE alone or combine with HBx both induced IL-6 expression. However, the protein expression of IL-8 was only found in ANE or ACO stimulation in the presence of HBx. In conclusion, BQ components activate AP-1 and NF-κB transcriptional factors and induced the HCC invasiveness markers expression at the mRNA and protein level. ANE combine with HBV synergistically induced AP-1 and NF-κB activation. We provide the possible molecular mechanism of betel nuts chewing and combine with viral factors in the development of HCC. Our clinical implication is betel but chewing in HBsAg carriers may increase the risk of HCC development. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T07:29:17Z (GMT). No. of bitstreams: 1 ntu-97-R94422013-1.pdf: 2415897 bytes, checksum: 8d7597e3626fb78eab08d4ecf2ee9716 (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 中文摘要------------------------------------------------i
英文摘要-----------------------------------------------iii 目錄-------------------------------------------------v 圖次--------------------------------------------------x 附錄---------------------------------------------------xiii 第一章 緒論 1.1 檳榔嚼食與口咽部腫瘤的關係---------------------------------------------1 1.2 檳榔塊之組成成分------------------------------------------------------------1 1.3 檳榔子萃取物的致癌性、突變性及基因毒性---------------------------2 1.4 檳榔鹼的致癌性、突變性及基因毒性------------------------------------3 1.5 活性氧所扮演的角色(ROS)-------------------------------------------------3 1.6 訊息傳導與肝癌之關連性---------------------------------------------------4 1.6.1 Ras/Raf/MEK/ERK訊息傳導對腫瘤形成之影響--------------4 1.6.2 AP-1及NF-κB之訊息傳導與肝癌之關係----------------------5 1.6.3 p53 腫瘤抑制基因---------------------------------------------------6 1.7 檳榔化學致癌性對肝臟之影響---------------------------------------------6 1.8 B型肝炎病毒與肝癌---------------------------------------------------------7 1.9 嚼食檳榔與肝癌關係之流行病學研究------------------------------------8 1.10 實驗動機與目的---------------------------------------------------------------9 第二章 實驗材料方法 2.0 實驗材料與藥品來源--------------------------------------------------------10 2.1 檳榔子之水萃取--------------------------------------------------------------11 2.2 細胞株與細胞培養-----------------------------------------------------------11 2.3 細胞生長評估-----------------------------------------------------------------12 2.3.1 MTT dye配製--------------------------------------------------------12 2.3.2 MTT assay ------------------------------------------------------------13 2.4 報導基因分析-----------------------------------------------------------------13 2.4.1 報導基因相關質體--------------------------------------------------------13 2.4.2 HBV相關質體-------------------------------------------------------14 2.4.3 HBV相關質體製備-------------------------------------------------15 2.4.4 質體轉染(Transfection)---------------------------------------------15 2.4.4.1 報導基因分析(Reporter assay)-------------------------15 2.4.5 Dual-Luciferase Reporter assay------------------------------------16 2.4.6 Bio-Rad protein assay -----------------------------------------------16 2.5 西方點墨法(Western Blotting)----------------------------------------------17 2.5.1 蛋白質表現-----------------------------------------------------------17 2.5.2 蛋白質的萃取--------------------------------------------------------17 2.5.3 配置膠體與電泳分析-----------------------------------------------17 2.5.4 蛋白質轉漬(Transfer)-----------------------------------------------18 2.5.5 抗體使用--------------------------------------------------------------18 2.6 聚合酶鏈鎖反應 (polymerase chain reaction)---------------------------19 2.6.1 RNA分離法----------------------------------------------------------19 2.6.2 RNA定量-------------------------------------------------------------19 2.6.3 RNA反轉錄(Reverse Transcription)------------------------------20 2.6.4 聚合酶鏈鎖反應 (polymerase chain reaction, PCR)-----------20 2.7 HBsAg and HBeAg assay----------------------------------------------------21 2.8 統計分析-----------------------------------------------------------------------22 第三章 實驗結果 3.1 檳榔子萃取物及檳榔素之肝細胞毒性 3.1.1 檳榔子萃取物之肝細胞毒性--------------------------------------23 3.1.2 檳榔素之肝細胞毒性-----------------------------------------------23 3.1.3 p53所扮演的角色---------------------------------------------------24 3.2 檳榔成份活化AP-1及NF-κB之機轉 3.2.1 檳榔萃取物與檳榔素活化AP-1----------------------------------25 3.2.2 檳榔子萃取物及檳榔素活化AP-1與PI3K之關係-----------25 3.2.2.1 檳榔子萃取物與檳榔素活化AP-1之作用無法由PI3K抑制劑LY294002所阻斷-----------------------------------------25 3.2.2.2 檳榔子萃取物與檳榔素活化AP-1之作用無法由PI3K抑劑劑Wortmannin所阻斷---------------------------------------26 3.2.3 檳榔子萃取物及檳榔素活化AP-1與PKC之關係-----------26 3.2.3.1 PKC抑制劑H7對檳榔子萃取物所活化之AP-1有抑制效果------------------------------------------------------------------ 27 3.2.3.2 PKC抑制劑H7對於檳榔素所活化之AP-1無抑制效果--------------------------------------------------------------------- 27 3.2.4 檳榔子萃取物及檳榔素活化AP-1與Ras-ERK訊息傳導之關係-----------------------------------------------------------------------27 3.2.4.1 檳榔子萃取物藉由Ras訊息傳導路徑活化AP-1---------28 3.2.4.2 檳榔素藉由Ras訊息傳導路徑活化AP-1------------------28 3.2.4.3 檳榔子萃取物藉由MEK/ERK訊息傳導路徑活化AP-1 --------------------------------------------------------------------- 29 3.2.4.4 檳榔素藉由ERK訊息傳導路徑活化AP-1 ----------------29 3.2.5 檳榔子萃取物與檳榔素皆可活化NF-κB-----------------------29 3.2.6 檳榔子萃取物活化NF-κB與PI3K之關係---------------------30 3.2.6.1 檳榔子萃取物活化NF-κB無法由PI3K抑制劑LY294002所阻斷------------------------------------------------------------ 30 3.2.6.2 檳榔子萃取物活化NF-κB無法由PI3K抑制劑Wortmanninn阻斷-----------------------------------------------30 3.2.7 檳榔子萃取物活化NF-κB與PKC之關係---------------------30 3.2.7.1 PKC抑制劑H7對於檳榔子萃取物所活化之NF-κB有抑制作用------------------------------------------------------------ 30 3.2.8 檳榔子萃取物活化NF-κB與Ras-ERK之關係----------------31 3.2.8.1 檳榔子萃取物活化NF-κB並無透過Ras之訊息傳導路徑--------------------------------------------------------------------- 31 3.2.9 檳榔子萃取物藉由MEK/ERK訊息傳導路徑活化NF-κB---31 3.3 活性氧及酵素對於檳榔子萃取物活化AP-1及NF-κB之影響 3.3.1 NAC (N-acetylcysteine)抑制檳榔子萃取物活化AP-1--------32 3.3.2 酯解酶(Esterase)抑制檳榔子萃取物活化AP-1----------------32 3.3.3 過氧化氫酶(Catalase)對檳榔子萃取物活化AP-1無抑制作用 --------------------------------------------------------------------------32 3.3.4 NAC、酯解酶及過氧化氫酶對於檳榔子萃取物活化NF-κB皆無抑制作用--------------------------------------------------------33 3.4 B型肝炎病毒X蛋白存在對檳榔成份活化AP-1/ NF-κB之協同(synergistic)及加成(additive)效應 3.4.1 基因型(genotype)A之B型肝炎病毒X蛋白(HBx)對檳榔子萃取物活化AP-1有協同效應(synergistic effects)----------------34 3.4.2 基因型(genotype)B之B型肝炎病毒X蛋白(HBx)對檳榔子萃取物活化AP-1有協同效應(synergistic effects)----------------34 3.4.3 基因型(genotype)A之B型肝炎病毒X蛋白(HBx)對檳榔素活化AP-1只有加成效應(additive effects)-------------------------34 3.4.4 基因型(genotype)B之B型肝炎病毒X蛋白(HBx)對檳榔素取 物活化AP-1只有加成效應(synergistic effects)----------------35 3.4.5 基因型(genotype) A之B型肝炎病毒X蛋白(HBx)對檳榔子萃取物活化NF-κB有協同效應(synergistic effects)-----------35 3.4.6 基因型(genotype) B之B型肝炎病毒X蛋白(HBx)對檳榔子萃取物活化NF-κB有協同效應(synergistic effects)-----------35 3.4.7 HBx蛋白在HuH7細胞中的表現--------------------------------36 3.5 B型肝炎病毒X蛋白存在下對檳榔成份活化AP-1/ NF-κB訊息傳導路徑之影響 3.5.1 HBx蛋白對檳榔子萃取物活化AP-1之協同效應可由MEK/ERK抑劑U0126阻斷---------------------------------------36 3.5.2 HBx蛋白對檳榔子萃取物活化NF-κB之協同效應部份可由MEK/ERK抑制劑U0126阻斷------------------------------------36 3.5.3 HBx蛋白在HuH7細胞中的表現--------------------------------37 3.6 HuH7細胞mRNA 產物 3.6.1 檳榔子萃取物誘導tPA, PAI-1及IL-6 mRNA表現-----------37 3.6.2 檳榔素誘導N-Cadherin及VCAM-1 mRNA表現-------------37 3.7 IL-6及IL-8蛋白表現--------------------------------------------------------38 3.8 檳榔成份對HBsAg及HBeAg濃度的影響------------------------------38 第四章 討論 4.1 檳榔子萃取物與檳榔素對於細胞生長的影響--------------------------40 4.2 檳榔成份活化AP-1 / NF-κB之機轉--------------------------------------41 4.3 活性氧對於檳榔子萃取物活化AP-1有較大的影響-------------------42 4.4 B型肝炎病毒X蛋白(HBx)對檳榔子萃取物活化AP-1/NF-κB有協同效應(synergistic effects) --------------------------------------------------43 4.5 不同基因型HBx蛋白之影響----------------------------------------------44 4.6 檳榔成份誘導HuH-7之mRNA及蛋白表現---------------------------45 4.7 檳榔成份對病毒複製的影響-----------------------------------------------46 第五章 總結---------------------------------------------------------------------------------48 參考文獻---------------------------------------------------------------------------------------50 圖次 Fig.1. Dose-dependent effects of ANE on cell proliferation in HuH7, HepG2 and primary hepatocyte.----------------------------------------------------------------60 Fig.2. Dose-dependent effects of Arecoline on cell proliferation in HuH7, HepG2 and primary hepatocyte -----------------------------------------------------------61 Fig.3. Effects of Pifithrin-α on ANE/Arecoline treated cell proliferation in HepG2. ----------------------------------------------------------------------------------------62 Fig.4. Activation of AP-1 binding site by (A) ANE (B) Arecoline in HuH7 cells.----------------------------------------------------------------------------------63 Fig.5. Fold activation of AP-1 binding site by ANE (A) and Arecoline (B) is resistant to inhibition by LY294002. --------------------------------------------64 Fig.6. Fold activation of AP-1 binding site by ANE (A) and Arecoline (B) is resistant to inhibition by Wortmannin -------------------------------------------65 Fig.7. PKC inhibitor H7 inhibits AP-1 binding site activation stimulated by ANE (A) but not Arecoline (B)----------------------------------------------------------66 Fig.8A. ANE induced AP-1 binding site activation is mediated via Ras pathway ----------------------------------------------------------------------------------------67 Fig.8B Arecoline induced AP-1 binding site activation is mediated via Ras pathway.-----------------------------------------------------------------------------68 Fig.9. ERK1/2 inhibitor U0126 inhibits AP-1 binding site activation stimulated by ANE (A) and Arecoline (B) ------------------------------------------------------69 Fig.10. Fold activation of NF-κB binding site by (A) ANE (B) Arecoline in HuH7 cells.----------------------------------------------------------------------------------70 Fig.11. Fold activation of NF-κB binding site by ANE is resistant to inhibition by LY294002----------------------------------------------------------------------------71 Fig.12. Fold activation of NF-κB binding site by ANE is resistant to inhibition by Wortmannin.-------------------------------------------------------------------------72 Fig.13. PKC inhibitor H7 partially inhibits NF-κB binding site activation stimulated by ANE.------------------------------------------------------------------------------73 Fig.14. Ras pathway does not involved in ANE induced NF-κB binding site activation.----------------------------------------------------------------------------74 Fig.15. ERK1/2 inhibitor U0126 inhibits NF-κB binding site activation stimulated by ANE.------------------------------------------------------------------------------75 Fig.16. ROS scavenger NAC (N-acetylcysteine) inhibits AP-1 binding site activation stimulated by ANE.----------------------------------------------------76 Fig.17. Esterase inhibits AP-1 binding site activation stimulated by ANE.----------77 Fig.18. AP-1 binding site activation stimulated by ANE is resistant to Catalase ----------------------------------------------------------------------------------------78 Fig.19. NF-κB binding site activation stimulated by ANE is resistant to NAC, Esterase and Catalase--------------------------------------------------------------79 Fig.20. Synergistic effects of ANE mediated AP-1 binding site activation by HBxA and HBxB ---------------------------------------------------------------------------80 Fig.21. Additive effects of Arecoline mediated AP-1 binding site activation by HBxA and HBxB. ------------------------------------------------------------------81 Fig.22. Synergistic effects of ANE mediated NF-κB binding site activation by HBxA and HBxB. ------------------------------------------------------------------82 Fig.23. Synergistic effects of ANE 800 ug/ml mediated AP-1 binding site activation by HBxA and HBxB was inhibited by MEK/ERK inhibitor (U0126) ------83 Fig.24. Synergistic effects of ANE 800 μg/ml mediated NF-κB binding site activation by 0.2 μg HBxA was partially inhibited by MEK/ERK inhibitor (U0126) ----------------------------------------------------------------------------- 84 Fig.25. Effects of ANE to mRNA expression of (A) Tissue plasminogen activator (B) PAI-1 and (C) IL-6.------------------------------------------------------------85 Fig.26. Effects of Arecoline to mRNA expression of (A) N-Cadherin (B) VCAM-1. ----------------------------------------------------------------------------------------86 Fig.27. Effects of ANE and Arecoline combine with HBx to IL-6 and IL-8 potein level expression.--------------------------------------------------------------------87 Fig.28. Inhibition of HBsAg and HBeAg expression in HuH-7 by (A)ANE and (B)Arecoline.------------------------------------------------------------------------88 Fig.29. (A)HBsAg and (B)HBeAg expression in HepG2.2.15 (HBV-producing cell line) stimulated by ANE-----------------------------------------------------------89 Fig.30. (A)HBsAg and (B)HBeAg expression in HepG2.2.15 stimulated by Arecoline.----------------------------------------------------------------------------90 Fig.31. (A)HBsAg and (B)HBeAg expression in high confluence of HepG2.2.15 cells stimulated by ANE-----------------------------------------------------------91 Fig.32. (A)HBsAg and (B)HBeAg expression in high confluence of HepG2.2.15 cells stimulated by Arecoline -----------------------------------------------------92 Fig.33. Possible signal transduction pathway of AP-1 activated by areca nut extract (ANE) and Arecoline (ACO).-----------------------------------------------------93 Fig.34. Possible signal transduction pathway of NF-κB activated by areca nut extract (ANE)-----------------------------------------------------------------------94 Fig.35. ANE-induced AP-1 and NF- | |
dc.language.iso | zh-TW | |
dc.title | 肝細胞中檳榔對於AP-1及NF-κB基因之調控 | zh_TW |
dc.title | Mechanism of AP-1 and NF-κB activation and signaling
by betel quid components in liver cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 吳慧琳(Hui-Lin Wu) | |
dc.contributor.oralexamcommittee | 李士元,許明倫,林俊彬 | |
dc.subject.keyword | 檳榔子萃取物,AP-1,NF-κB,B型肝炎病毒X 蛋白,肝癌, | zh_TW |
dc.subject.keyword | Areca nut extract,AP-1,NF-κB,HBx,HCC, | en |
dc.relation.page | 100 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2008-07-03 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床牙醫學研究所 | zh_TW |
顯示於系所單位: | 臨床牙醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 2.36 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。